Concentra Group Holdings Parent, Inc. (CON)

Current Report Filed: 2026-05-07

Concentra declared a quarterly cash dividend of $0.0625 per share payable June 9, 2026, indicating confidence in cash generation and shareholder return commitment despite being a relatively young public company (Commission File Number 001-42188).
Q1 2026 earnings announcement signals the company is maintaining regular financial reporting cadence and investor communication practices, with both press release and investor presentation provided on the same date.
The company continues to operate profitably with sufficient cash flow to support dividend payments in the near-term, suggesting stable operational performance in the first quarter of 2026.

Quarterly Report Filed: 2026-05-07

The filing contains extensive XBRL data structure tags indicating detailed financial reporting across multiple segments (Occupational Health Centers and Onsite Health Clinics) and debt instruments, suggesting a complex capital structure with 6.875% senior notes due July 2032 and multiple credit facilities.
The presence of derivative financial instruments (swaps and collars) classified as Level 2 fair value measurements across both current and noncurrent liabilities indicates active management of interest rate or currency exposure, though the economic impact requires viewing the full narrative.
The company maintains variable interest entity relationships and related party transactions tracked at the reporting level, which could indicate subsidiary consolidation complexities or joint venture arrangements requiring careful scrutiny of consolidation methodology.

Current Report Filed: 2026-04-30

All three director proposals passed with strong shareholder support, with Vipin Gopal receiving 119.2M votes for (98.0% approval) and William K. Newton receiving 115.6M votes for (96.8% approval), indicating solid confidence in board leadership and continuity.
Marc R. Watkins, MD faced notably higher opposition with 21.8M votes against (18.2% dissent rate), suggesting some investor concern about this director's performance or qualifications that warrants monitoring in future periods.
Executive compensation received strong advisory approval with 114.2M votes for (95.6% support), indicating stockholders are satisfied with current pay practices and incentive structures for named executive officers.
PricewaterhouseCoopers LLP was ratified as auditor with overwhelming support (121.6M votes for, 99.7% approval) and zero broker non-votes, reflecting strong confidence in audit oversight and no audit-related controversies.

Current Report Filed: 2026-04-14

Concentra Group Holdings Parent, Inc. announced the retirement of its Executive Vice President and Chief Medical Officer, Dr. John Anderson, effective December 31, 2026. The company plans to enter into a Consulting Agreement with Dr. Anderson to support the transition of his responsibilities.
The company issued a press release on April 14, 2026, regarding Dr. Anderson's retirement, which indicates the event is being communicated to the market.
The departure of a C-level executive such as the Chief Medical Officer could signal changes in the company's strategic direction or operations, and investors should monitor any updates on the transition and the appointment of a new Chief Medical Officer.

Current Report Filed: 2026-02-26

Concentra Group Holdings Parent, Inc. reported its Q4 2025 and full-year 2025 financial results, indicating the company's performance during the period.
The company announced a cash dividend of $0.0625 per share, payable on March 19, 2026 to stockholders of record as of March 12, 2026.
The filing provides additional financial and operational details that may be of interest to investors in evaluating the company's performance and future prospects.

Annual Report Filed: 2026-02-26

The company reported a 23.3% increase in general and administrative expenses in 2025, which could impact profitability.
Concentra Group Holdings Parent, Inc. has a significant amount of long-term debt, with current and non-current portions totaling 23.3% of the balance sheet.
The company announced a share repurchase program in November 2025, which could signal management's confidence in the business.

Current Report Filed: 2026-01-28

The company issued preliminary, unaudited results for Q4 and FY 2025, which suggests the company may be providing an earnings update or pre-announcement.
The company published a presentation and investor book in connection with the press release, indicating they are likely preparing for an investor event or earnings call.
As this is an 8-K filing, the information disclosed is likely material and could impact the stock price, depending on the actual results and company outlook.

Current Report Filed: 2026-01-12

Concentra Group Holdings Parent, Inc. reported preliminary, unaudited results for Q4 2025, which will be presented at the J.P. Morgan Healthcare Conference.
The company has not provided full financial results or guidance, indicating this is an interim operational update rather than a comprehensive earnings report.
Investors should look for additional details on Concentra's financial and operational performance when the company releases its full Q4 2025 results.

Important Information